High-throughput Serological Testing of Antibodies Platform

Launched by ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE · Apr 18, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on developing new and efficient ways to test for antibodies against various respiratory viruses, especially those that could cause pandemics. Researchers want to create a system that can quickly and accurately measure the body's immune response to both common viruses, like seasonal flu and COVID-19, as well as emerging threats, such as certain types of avian influenza and Zika virus. To do this, they will use special devices to collect blood samples from participants, which will be compared to traditional blood collection methods.

To be eligible for this study, you need to be between 20 and 65 years old. However, if you have a weakened immune system, chronic inflammatory conditions, or have received certain treatments in the past year that affect your immune response, you won’t be able to participate. If you join the study, you'll help researchers improve testing methods that could enhance our preparedness for future viral outbreaks. The trial is currently not recruiting participants, but it aims to provide important insights into how we can better respond to health emergencies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult Cohort - between 20 and 65 years of age Pediatric Cohort - between 2 and 10 years of age Signed consent form by the subject for adults or by caregivers for children
• Exclusion Criteria:
• • 1. subjects with an immunocompromised status, such as immunodeficiency disorders or those undergoing immunosuppressant treatments
• • 2. subjects with underlying chronic inflammatory conditions (i.e., autoimmune disorders, chronic gastrointestinal, and rheumatic conditions)
• • 3. subjects who have received immunomodulatory treatment within the past year.